FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4234892542> ?p ?o ?g. }

• W4234892542 endingPage "2004" @default.
• W4234892542 startingPage "1999" @default.
• W4234892542 abstract "Antiprothrombin and anti–β2-glycoprotein I (β2-GPI) antibodies belong to the family of antiphospholipid (APL) antibodies and represent the phospholipid-dependent inhibitors of coagulation. They may be distinguished by analyzing the coagulation profiles generated by the comparison of the ratios of two coagulation tests, the Kaolin Clotting Time (KCT) and the dilute Russell's Viper Venom Time (dRVVT), commonly adopted for their diagnosis. The KCT profile is caused by antiprothrombin antibodies, whereas anti–β2-GPI antibodies are responsible for the dRVVT coagulation profile. The presence of aPL antibodies is frequently associated with acquired resistance to activated Protein C (APC-R), but limited information is available regarding the role of the different antibodies in its development. We studied the time-course of activated Factor V (FVa) generation and inactivation in the plasma of 42 patients with well-defined phospholipid-dependent inhibitors of coagulation: 24 displayed the dRVVT coagulation profile, whereas the other 18 cases showed the KCT profile. In normal pooled plasma, the peak values of FVa (mean ± standard deviation, [SD]: 16.307 ± 4.372 U/mL) were reached in 4 to 5 minutes and an almost complete inactivation (0.088 ± 0.123 U/mL) was obtained within 20 minutes. At this time point, values of residual FVa exceeding 2 SD the mean of controls (0.344 U/mL) were considered abnormal. Patients belonging to the KCT coagulation profile group reached the maximal amount of FVa in plasma (22.740 ± 7.693 U/mL, P = not significant v controls) within 4 to 5 minutes; at 20 minutes, the residual amount of FVa in plasma ranged from 0 to 1.09 U/mL (0.293 ± 0.298; P = .027), but it was found abnormal in only six of the 18 cases. The time-course of FVa in plasma of patients belonging to the dRVVT coagulation profile group differed from that of normal controls in that the peak values (10.955 ± 5.092 U/mL) were reached at 10 minutes and the amount of residual FVa at 20 minutes ranged from 0.320 to 14.450 U/ml (2.544 ± 3.580 U/mL;P = .0191 v normal controls and P = .0114v KCT group patients). Twenty of the 24 patients belonging to the dRVVT profile group had an abnormal inactivation of FVa (χ2 = 0.001 v KCT group patients). History of venous thrombosis was experienced by 15 patients: an abnormal rate of FVa inactivation was found in 11 of them (73%) versus 15 of the 27 cases without thrombosis (56%) (x2= 0.2556). The effect of affinity-purified IgG phospholipid-dependent inhibitors of coagulation on the time-course of FVa generation and inactivation in normal plasma was also investigated. Anti–β2-GPI, but not antiprothrombin antibodies, hampered the inactivation of FVa by endogenous APC, thus reproducing the behavior of the original plasmas. This effect was strictly β2-GPI–dependent. In conclusion, our findings confirm that anti–β2-GPI antibodies identify patients with phospholipid-dependent inhibitors of coagulation at increased risk of thrombosis and suggest acquired APC-R as a possible explanation of the pathogenesis of the thromboembolic events." @default.
• W4234892542 created "2022-05-12" @default.
• W4234892542 creator A5011382851 @default.
• W4234892542 creator A5069072959 @default.
• W4234892542 creator A5079910766 @default.
• W4234892542 date "1998-03-15" @default.
• W4234892542 modified "2023-09-28" @default.
• W4234892542 title "Differential Effects of Anti–β2-Glycoprotein I and Antiprothrombin Antibodies on the Anticoagulant Activity of Activated Protein C" @default.
• W4234892542 cites W1482317494 @default.
• W4234892542 cites W1812735750 @default.
• W4234892542 cites W1991153412 @default.
• W4234892542 cites W2007914723 @default.
• W4234892542 cites W2017528387 @default.
• W4234892542 cites W2017687893 @default.
• W4234892542 cites W2021306080 @default.
• W4234892542 cites W2022510326 @default.
• W4234892542 cites W2031534496 @default.
• W4234892542 cites W2034787765 @default.
• W4234892542 cites W2041297457 @default.
• W4234892542 cites W2076944027 @default.
• W4234892542 cites W2101831374 @default.
• W4234892542 cites W2113891001 @default.
• W4234892542 cites W2409945121 @default.
• W4234892542 cites W2415371444 @default.
• W4234892542 cites W2437357051 @default.
• W4234892542 cites W4296981399 @default.
• W4234892542 cites W4298354788 @default.
• W4234892542 cites W458440 @default.
• W4234892542 doi "https://doi.org/10.1182/blood.v91.6.1999.1999_1999_2004" @default.
• W4234892542 hasPublicationYear "1998" @default.
• W4234892542 type Work @default.
• W4234892542 citedByCount "3" @default.
• W4234892542 crossrefType "journal-article" @default.
• W4234892542 hasAuthorship W4234892542A5011382851 @default.
• W4234892542 hasAuthorship W4234892542A5069072959 @default.
• W4234892542 hasAuthorship W4234892542A5079910766 @default.
• W4234892542 hasBestOaLocation W42348925421 @default.
• W4234892542 hasConcept C126322002 @default.
• W4234892542 hasConcept C134018914 @default.
• W4234892542 hasConcept C159654299 @default.
• W4234892542 hasConcept C185592680 @default.
• W4234892542 hasConcept C203014093 @default.
• W4234892542 hasConcept C2776046644 @default.
• W4234892542 hasConcept C2778382381 @default.
• W4234892542 hasConcept C2780868729 @default.
• W4234892542 hasConcept C2781287897 @default.
• W4234892542 hasConcept C71924100 @default.
• W4234892542 hasConcept C77171857 @default.
• W4234892542 hasConceptScore W4234892542C126322002 @default.
• W4234892542 hasConceptScore W4234892542C134018914 @default.
• W4234892542 hasConceptScore W4234892542C159654299 @default.
• W4234892542 hasConceptScore W4234892542C185592680 @default.
• W4234892542 hasConceptScore W4234892542C203014093 @default.
• W4234892542 hasConceptScore W4234892542C2776046644 @default.
• W4234892542 hasConceptScore W4234892542C2778382381 @default.
• W4234892542 hasConceptScore W4234892542C2780868729 @default.
• W4234892542 hasConceptScore W4234892542C2781287897 @default.
• W4234892542 hasConceptScore W4234892542C71924100 @default.
• W4234892542 hasConceptScore W4234892542C77171857 @default.
• W4234892542 hasIssue "6" @default.
• W4234892542 hasLocation W42348925421 @default.
• W4234892542 hasOpenAccess W4234892542 @default.
• W4234892542 hasPrimaryLocation W42348925421 @default.
• W4234892542 hasRelatedWork W1970620280 @default.
• W4234892542 hasRelatedWork W2010893008 @default.
• W4234892542 hasRelatedWork W2030767014 @default.
• W4234892542 hasRelatedWork W2281899782 @default.
• W4234892542 hasRelatedWork W2336264902 @default.
• W4234892542 hasRelatedWork W2347867142 @default.
• W4234892542 hasRelatedWork W2418262919 @default.
• W4234892542 hasRelatedWork W2748952813 @default.
• W4234892542 hasRelatedWork W2769424276 @default.
• W4234892542 hasRelatedWork W4234892542 @default.
• W4234892542 hasVolume "91" @default.
• W4234892542 isParatext "false" @default.
• W4234892542 isRetracted "false" @default.
• W4234892542 workType "article" @default.